Objective: To compare the efficacy of imipramine and fluvoxamine in inpatients from two centers suffering from a depressive disorder according to DSM IV criteria. Methods: The study included 141 patients with a depressive disorder according to DSM IV criteria. After a drug-free and placebo run-in period of 1 week, patients were randomized to imipramine or fluvoxamine; doses of both drugs were adjusted to a predefined target blood level. Efficacy was evaluated 4 weeks after attaining predefined adequate plasma level. Results: The mean age of the study group (47 males, 94 females) was 51.8 (range 19-65) years. Of these 141 patients, 56 had episode duration longer than 1 year, 48 had mood congruent psychotic features, and 138 patients received medication. Seven patients did not complete the medication trial. The total number of patients using concurrent medication was 12/138 (8.6%). On the primary outcome criteria patients on imipramine improved significantly better on the change of illness severity score of the CGI (χ 2 exact trend test=4.089, df=1, P=0.048). There was no significant difference in 50% or more reduction on the HRSD, the other primary outcome criterion. On the secondary outcome criteria the mean reduction of the HRSD scores was significantly larger in the imipramine group than in the fluvoxamine group (mean difference=3.1, standard error (SE)=1.4, t=2.15, df=136, P=0.033). There was no significant difference in the number of patients with an HRSD ≤7 at the final evaluation. Conclusions: In depressed inpatients imipramine is more efficacious than fluvoxamine. Both drugs were well tolerated by all patients.

Concentration targeted trial, Depressive disorder, Fluvoxamine, Imipramine, Inpatients, Major depression
dx.doi.org/10.1007/s00213-004-1853-3, hdl.handle.net/1765/63859
Psychopharmacology
Department of Psychiatry

van den Broek, W.W, Birkenhäger, T.K, Mulder, P.G.H, Bruijn, J.A, & Moleman, P. (2004). A double-blind randomized study comparing imipramine with fluvoxamine in depressed inpatients. Psychopharmacology, 175(4), 481–486. doi:10.1007/s00213-004-1853-3